Healthcare provider profile · identity verified

Danielle Grace Raines, APRN

Nurse Practitioner · CHARLESTON, WV · NPI 1477079705

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	315	31
Pantoprazole Sodium	Pantoprazole Sodium	185	44
Atorvastatin Calcium	Atorvastatin Calcium	161	44
Levothyroxine Sodium	Levothyroxine Sodium	136	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	127	17
Sertraline Hcl	Sertraline Hcl	127	32
Furosemide	Furosemide	126	32
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	101	32
Lorazepam	Lorazepam	83	16
Amlodipine Besylate	Amlodipine Besylate	81	22
Eliquis	Apixaban	74	19
Trazodone Hcl	Trazodone Hcl	63	15
Ondansetron Hcl	Ondansetron Hcl	60	30
Duloxetine Hcl	Duloxetine Hcl	57	16
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	56	14
Mirtazapine	Mirtazapine	55	24
Potassium Chloride	Potassium Chloride	55	19
Omeprazole	Omeprazole	53	18
Clopidogrel	Clopidogrel Bisulfate	48	13
Lisinopril	Lisinopril	47	suppressed
Metoprolol Succinate	Metoprolol Succinate	46	19
Torsemide	Torsemide	46	11
Jardiance	Empagliflozin	43	suppressed
Januvia	Sitagliptin Phosphate	42	suppressed
Losartan Potassium	Losartan Potassium	41	13
Tamsulosin Hcl	Tamsulosin Hcl	40	12
Levetiracetam	Levetiracetam	36	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	35	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	35	suppressed
Prednisone	Prednisone	35	24
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Buspirone Hcl	Buspirone Hcl	34	11
Metoprolol Tartrate	Metoprolol Tartrate	34	11
Rexulti	Brexpiprazole	32	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	30	suppressed
Divalproex Sodium	Divalproex Sodium	27	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	27	15
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Diclofenac Sodium	Diclofenac Sodium	25	suppressed
Vascepa	Icosapent Ethyl	25	suppressed
Baclofen	Baclofen	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	23	23
Humalog Kwikpen U-100	Insulin Lispro	23	suppressed
Memantine Hcl	Memantine Hcl	23	suppressed
Metformin Hcl	Metformin Hcl	23	suppressed
Tramadol Hcl	Tramadol Hcl	22	12
Carvedilol	Carvedilol	21	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Famotidine	Famotidine	19	suppressed
Montelukast Sodium	Montelukast Sodium	19	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Nystatin	Nystatin	18	11
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Aripiprazole	Aripiprazole	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Lidocaine	Lidocaine	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Glipizide	Glipizide	16	suppressed
Lacosamide	Lacosamide	16	suppressed
Olanzapine	Olanzapine	16	suppressed
Oxcarbazepine	Oxcarbazepine	16	suppressed
Risperidone	Risperidone	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	12
Xarelto	Rivaroxaban	14	suppressed
Albuterol Sulfate	Albuterol Sulfate	13	suppressed
Alprazolam	Alprazolam	13	suppressed
Ceftriaxone	Ceftriaxone Sodium	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Insulin Glargine Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Levemir	Insulin Detemir	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Levalbuterol Hcl	Levalbuterol Hcl	11	suppressed
Linzess	Linaclotide	11	suppressed
Spironolactone	Spironolactone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error